Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies

BACKGROUND: Isocitrate dehydrogenase (IDH) is an appealing target for anticancer therapy, and IDH (IDH1/2) inhibitors have been approved for targeted therapy of acute myeloid leukemia (AML) and Cholangiocarcinoma. The therapeutic potential of IDH inhibitors for non‐small‐cell lung cancer (NSCLC) pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shuchen, Zhu, Honglin, Jin, Meizi, Yuan, Hongling, Liu, Zhenzhen, Li, Jielin, Zhang, Xiang, Meng, Lihui, Li, Ting, Diao, Yuzhu, Gao, Hong, Hong, Chengyu, Zhu, Xinjiang, Zheng, Jian, Li, Fei, Niu, Yanling, Ma, Tonghui, Li, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678110/
https://www.ncbi.nlm.nih.gov/pubmed/35526267
http://dx.doi.org/10.1002/cam4.4764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678110/
https://www.ncbi.nlm.nih.gov/pubmed/35526267
http://dx.doi.org/10.1002/cam4.4764

Ejemplares similares